• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Booster vaccination: the role of reduced antigen content vaccines as a preschool booster.加强免疫接种:抗原含量降低的疫苗作为学龄前儿童加强剂的作用。
Biomed Res Int. 2014;2014:541319. doi: 10.1155/2014/541319. Epub 2014 Feb 11.
2
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.一项 III 期、开放性标签、随机多中心研究,旨在评估在英国 3 至 4 岁健康儿童中,同时接种麻疹-腮腺炎-风疹疫苗时,两种不同低剂量抗原白喉-破伤风-无细胞百日咳-脊髓灰质炎疫苗加强剂量的免疫原性和安全性。
Vaccine. 2018 Apr 19;36(17):2300-2306. doi: 10.1016/j.vaccine.2018.03.021. Epub 2018 Mar 22.
3
Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.十年期联合低抗原含量白喉-破伤风-无细胞百日咳和灭活脊髓灰质炎病毒加强疫苗(dTpa-IPV)在健康成年人中的免疫原性和反应原性。
Vaccine. 2015 May 21;33(22):2594-601. doi: 10.1016/j.vaccine.2015.03.104. Epub 2015 Apr 14.
4
Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV).重复接种低抗原含量的白喉-破伤风-无细胞百日咳和脊髓灰质炎疫苗(dTpa-IPV;百白破脊髓灰质炎联合疫苗[加强型])。
Hum Vaccin. 2010 Jul;6(7):554-61. doi: 10.4161/hv.6.7.11760.
5
Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.联合低抗原含量白喉-破伤风-无细胞百日咳和脊髓灰质炎疫苗(dTpa-IPV)用于成人加强免疫接种。
Vaccine. 2005 May 25;23(28):3657-67. doi: 10.1016/j.vaccine.2005.02.013.
6
Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age.抗原含量降低的白喉-破伤风-无细胞百日咳疫苗作为2岁前接种白喉-破伤风-全细胞百日咳疫苗的4至7岁儿童加强针的反应原性和免疫原性。
Vaccine. 1999 Jun 4;17(20-21):2620-7. doi: 10.1016/s0264-410x(99)00065-1.
7
Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.吸附无细胞百白破灭活、全细胞百日咳和破伤风联合疫苗(Boostrix®):作为单剂加强免疫的特性和用途介绍。
Drugs. 2012 Sep 10;72(13):1765-91. doi: 10.2165/11209630-000000000-00000.
8
Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.白喉和破伤风类毒素联合全细胞百日咳疫苗或无细胞百日咳疫苗进行初次免疫,对15至21月龄儿童一剂含基因灭活百日咳毒素的无细胞百日咳疫苗加强免疫安全性和免疫原性的影响。意大利重组无细胞百日咳疫苗研究多中心小组
J Pediatr. 1995 Aug;127(2):238-43. doi: 10.1016/s0022-3476(95)70301-2.
9
Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.母亲接种白喉-破伤风-无细胞百日咳疫苗对幼儿百日咳加强免疫反应的影响:一项随机试验的随访。
Vaccine. 2021 Mar 12;39(11):1598-1608. doi: 10.1016/j.vaccine.2021.02.001. Epub 2021 Feb 19.
10
Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine.使用低抗原含量白喉破伤风无细胞百白破-灭活脊髓灰质炎疫苗对4至8岁儿童进行加强免疫接种及1年随访
Eur J Pediatr. 2007 Dec;166(12):1229-36. doi: 10.1007/s00431-006-0403-x. Epub 2007 Jan 18.

引用本文的文献

1
Mycobacterium-Induced Th1, Helminths-Induced Th2 Cells and the Potential Vaccine Candidates for Allergic Asthma: Imitation of Natural Infection.分枝杆菌诱导的 Th1、寄生虫诱导的 Th2 细胞与变应性哮喘的潜在疫苗候选物:模拟自然感染。
Front Immunol. 2021 Aug 3;12:696734. doi: 10.3389/fimmu.2021.696734. eCollection 2021.
2
Decennial diphtheria-tetanus adult boosters: are they really necessary?十年一次的成人白喉-破伤风加强疫苗接种:真的有必要吗?
J Prev Med Hyg. 2015 Jun 10;56(1):E44-8.
3
Safety and reactogenicity of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b (DTPa-IPV/Hib) vaccine in healthy Vietnamese toddlers: An open-label, phase III study.白喉-破伤风-无细胞百日咳-灭活脊髓灰质炎病毒- b型流感嗜血杆菌联合疫苗(DTPa-IPV/Hib)在越南健康幼儿中的安全性和反应原性:一项开放标签的III期研究。
Hum Vaccin Immunother. 2016 Mar 3;12(3):655-7. doi: 10.1080/21645515.2015.1084451.
4
Pertussis.百日咳
Hum Vaccin Immunother. 2015;11(1):108-17. doi: 10.4161/hv.34364. Epub 2014 Nov 1.

本文引用的文献

1
Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children.对2、4、6和18 - 19月龄接种的无细胞百白破-灭活脊髓灰质炎病毒//b型流感嗜血杆菌结合疫苗进行长期免疫原性评估,以及对4至6岁泰国儿童作为加强剂量接种的无细胞百白破-灭活脊髓灰质炎病毒疫苗的免疫原性和安全性评估。
Southeast Asian J Trop Med Public Health. 2012 May;43(3):687-98.
2
Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy.将含低剂量抗原的白喉-破伤风-无细胞百日咳-灭活脊髓灰质炎疫苗与麻疹-腮腺炎-风疹-水痘疫苗联合用于学龄前儿童加强免疫:根据婴儿期 2+1 程序进行初免儿童的随机对照试验。
Hum Vaccin Immunother. 2012 Mar;8(3):355-62. doi: 10.4161/hv.18650. Epub 2012 Feb 13.
3
Combination vaccines.联合疫苗
J Glob Infect Dis. 2011 Jan;3(1):63-72. doi: 10.4103/0974-777X.77298.
4
Recurrence of extensive injection site reactions following DTPa or dTpa vaccine in children 4-6 years old.儿童 4-6 岁时 DTPa 或 dTpa 疫苗接种后广泛注射部位反应的复发。
Vaccine. 2011 Jun 6;29(25):4230-7. doi: 10.1016/j.vaccine.2011.03.088. Epub 2011 Apr 15.
5
Spotlight on Tdap₅ vaccine (Covaxis®) as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis: in children (aged ≥4 years), adolescents, and adults.聚焦 Tdap₅ 疫苗(Covaxis®)作为预防破伤风、白喉和百日咳的单一加强免疫接种:用于儿童(≥4 岁)、青少年和成人。
Paediatr Drugs. 2011 Apr 1;13(2):133-5. doi: 10.2165/11206990-000000000-00000.
6
General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP).一般预防接种建议——免疫实施咨询委员会(ACIP)的建议。
MMWR Recomm Rep. 2011 Jan 28;60(2):1-64.
7
Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010.美国免疫实施咨询委员会关于破伤风类毒素、白喉类毒素和无细胞百日咳(Tdap)疫苗使用的更新建议,2010 年。
MMWR Morb Mortal Wkly Rep. 2011 Jan 14;60(1):13-5.
8
Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.十年一次给予低含量抗原的白喉破伤风类毒素和无细胞百日咳疫苗在年轻人中的效果。
Clin Infect Dis. 2010 Sep 15;51(6):656-62. doi: 10.1086/655825.
9
DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa): A Review of its Use as Primary and Booster Vaccination.DTaP-HBV-IPV/Hib 联合疫苗(百白破-乙肝-脊灰- Hib 联合疫苗):作为基础和加强免疫接种的应用评价。
Drugs. 2010 May 28;70(8):1021-58. doi: 10.2165/11204830-000000000-00000.
10
Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV).重复接种低抗原含量的白喉-破伤风-无细胞百日咳和脊髓灰质炎疫苗(dTpa-IPV;百白破脊髓灰质炎联合疫苗[加强型])。
Hum Vaccin. 2010 Jul;6(7):554-61. doi: 10.4161/hv.6.7.11760.

加强免疫接种:抗原含量降低的疫苗作为学龄前儿童加强剂的作用。

Booster vaccination: the role of reduced antigen content vaccines as a preschool booster.

作者信息

Gabutti Giovanni, Trucchi Cecilia, Conversano Michele, Zivelonghi Giambattista, Zoppi Giorgio

机构信息

Department of Prevention, O.U. Hygiene and Public Health, LHU 4 "Chiavarese"-Liguria Region, Corso Dante 163, Chiavari, 16043 Genoa, Italy.

Department of Health Sciences, University of Genova, Via Pastore 1, 16132 Genoa, Italy.

出版信息

Biomed Res Int. 2014;2014:541319. doi: 10.1155/2014/541319. Epub 2014 Feb 11.

DOI:10.1155/2014/541319
PMID:24678509
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3941168/
Abstract

The need for boosters for tetanus, diphtheria, pertussis, and polio, starting from preschool age, is related to the waning immune protection conferred by vaccination, the elimination/reduction of natural boosters due to large-scale immunization programs, and the possibility of reintroduction of wild agents from endemic areas. Taking into account the relevance of safety/tolerability in the compliance with vaccination among the population, it have been assessed whether today enough scientific evidences are available to support the use of dTap-IPV booster in preschool age. The review of the literature was conducted using the PubMed search engine. A total of 41 works has been selected; besides, the documentation produced by the World Health Organization, the European Centre for Disease Control, and the Italian Ministry of Health has been consulted. Many recent papers confirm the opportunity to use a low antigenic dose vaccine starting from 4 to 6 years of age. There is also evidence that 10 years after immunization the rate of seroprotected subjects against diphtheria does not differ significantly between those vaccinated with paediatric dose (DTaP) or reduced dose (dTaP or dTap) product. The dTpa vaccine is highly immunogenic for diphtheria toxoids regardless of prior vaccination history (2 + 1 and 3 + 1 schedules).

摘要

从学龄前开始就需要接种破伤风、白喉、百日咳和脊髓灰质炎加强疫苗,这与疫苗接种所提供的免疫保护减弱、大规模免疫规划导致自然加强因素的消除/减少以及从流行地区重新引入野生病原体的可能性有关。考虑到安全性/耐受性在人群疫苗接种依从性中的相关性,评估了目前是否有足够的科学证据支持在学龄前使用白百破-灭活脊髓灰质炎疫苗加强剂。使用PubMed搜索引擎对文献进行了综述。共筛选出41篇研究;此外,还查阅了世界卫生组织、欧洲疾病控制中心和意大利卫生部发布的文件。许多近期论文证实了从4至6岁开始使用低抗原剂量疫苗的合理性。也有证据表明,免疫接种10年后,接种儿童剂量(DTaP)或减量(dTaP或dTap)产品的人群中,对白喉具有血清保护作用的受试者比例没有显著差异。无论既往接种史如何(2+1和3+1接种程序),dTpa疫苗对白喉类毒素都具有高度免疫原性。